Your Messages Inbox
Your Article Summary
See Latest ArticlesAfinitor and Sandostatin LAR Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months
Novartis, 06/25/09
New data demonstrate that treatment with Afinitor Tablets in combination with Sandostatin LAR and Afinitor monotherapy may have the potential to control tumor growth in patients with advanced pancreatic neuroendocrine tumors. These results will be presented at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor